Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus IRBESARTAN HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus IRBESARTAN HYDROCHLOROTHIAZIDE.
BENICAR HCT vs IRBESARTAN HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Irbesartan is an angiotensin II receptor antagonist that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Oral, 150 mg irbesartan/12.5 mg hydrochlorothiazide once daily, titrated to 300 mg irbesartan/25 mg hydrochlorothiazide once daily based on BP response.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Irbesartan: 11–15 hours terminal half-life; supports once-daily dosing with steady state by 3 days. Hydrochlorothiazide: 6–15 hours terminal half-life; prolonged in renal impairment (up to 20+ hours) requiring dose adjustment.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Irbesartan: primarily fecal (80%) via biliary excretion, with ~20% renal. Hydrochlorothiazide: primarily renal (≥95% as unchanged drug) via tubular secretion.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB